Bristol-Myers Squibb Company (BVL:BMYUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 453.90B +35.8% |
| Revenue (ttm) | 167.96B +3.1% |
| Net Income | 31.70B +83.8% |
| EPS | 15.51 +82.7% |
| Shares Out | n/a |
| PE Ratio | 14.32 |
| Forward PE | 9.96 |
| Dividend | 8.81 (4.17%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 62.56 |
| Day's Range | n/a |
| 52-Week Range | 43.50 - 62.56 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About BVL:BMYUS
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
News
Bristol Myers price target raised to $71 from $66 at BofA
BofA raised the firm’s price target on Bristol Myers (BMY) to $71 from $66 and keeps a Buy rating on the shares. After a “strong” Q2 the pipeline story remains…
Bristol Myers price target raised to $59 from $54 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Bristol Myers (BMY) to $59 from $54 and keeps a Neutral rating on the shares. Bristol Myers delivered a…
Bristol Myers price target raised to $73 from $67 at JPMorgan
JPMorgan raised the firm’s price target on Bristol Myers (BMY) to $73 from $67 and keeps an Overweight rating on the shares.
Bristol Myers price target raised to $75 from $72 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Bristol Myers (BMY) to $75 from $72 and keeps a Buy rating on the shares. While the Q2 beat raises…
Bristol Myers price target raised to $65 from $60 at Wells Fargo
Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps an Equal Weight rating on the shares. Despite a “beat and raise” quarter,…
Bristol-Myers Squibb Company Earnings Call Transcript: Q2 2026
Q2 2026 saw robust 14% growth in the portfolio, driving a 5% revenue increase to $13B and prompting raised full-year guidance. Key products like ELIQUIS, REBLOZYL, and CAMZYOS posted strong gains, while pivotal pipeline readouts and regulatory milestones are expected by year-end.
Bristol-Myers Squibb Company Earnings release: Q2 2026
Bristol-Myers Squibb Company released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Bristol-Myers Squibb Company Slides: Q2 2026
Bristol-Myers Squibb Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Bristol-Myers Squibb Company Quarterly report: Q2 2026
Bristol-Myers Squibb Company has published its Q2 2026 quarterly earnings report on July 30, 2026.
Bristol Myers Lifts Outlook as Profit, Revenue Rise
Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven by strong sales of bl...
Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat
Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Second Quarter Financial Results for 2026.
Bristol Myers Squibb (BMY) Adopts Nvidia’s AI Computing System for Drug Discoveries
Artificial intelligence is helping bring medications to market.
Bristol Myers to expand compute infrastructure to deploy Nvidia DGX SuperPOD
Bristol Myers Squibb (BMY) announced it will expand its compute infrastructure to deploy an Nvidia (NVDA) DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and…
Bristol Myers buys Nvidia's latest AI computing system for drug research
Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and developmen...
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
Technical indicators show encouraging signs for the three stocks.
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
3 Stocks to Invest In to Rebalance Your Portfolio
#TheMorningFilter #PortfolioRebalance #StockInvesting These value stocks can balance portfolios heavy in growth stocks—and they're undervalued, too. Watch The Morning Filter: https://www.youtube.com/l...
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage hea...
Bristol-Myers Squibb Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key pipeline programs in oncology, hematology, cardiovascular, and neuroscience are advancing, with pivotal trial readouts expected in the near term. AI-driven trial optimization, robust business development, and a focus on durable growth underpin the strategy. Multiple late-stage assets, including milvexian, COBENFY, and Adempas, are nearing critical milestones.